Progyny, Inc. (NASDAQ:PGNY) Director Norman Payson Sells 8,330 Shares of Stock

Progyny, Inc. (NASDAQ:PGNYGet Rating) Director Norman Payson sold 8,330 shares of the company’s stock in a transaction on Wednesday, April 20th. The stock was sold at an average price of $43.91, for a total value of $365,770.30. Following the sale, the director now owns 505,776 shares of the company’s stock, valued at approximately $22,208,624.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Norman Payson also recently made the following trade(s):

  • On Thursday, April 7th, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $46.79, for a total value of $389,760.70.
  • On Wednesday, March 16th, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $44.99, for a total value of $374,766.70.
  • On Wednesday, March 9th, Norman Payson sold 8,510 shares of Progyny stock. The stock was sold at an average price of $45.50, for a total value of $387,205.00.
  • On Wednesday, March 2nd, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $44.00, for a total value of $366,520.00.
  • On Wednesday, February 23rd, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $35.30, for a total value of $294,049.00.
  • On Wednesday, February 16th, Norman Payson sold 8,330 shares of Progyny stock. The stock was sold at an average price of $40.49, for a total value of $337,281.70.
  • On Wednesday, February 9th, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $40.35, for a total value of $336,115.50.
  • On Wednesday, February 2nd, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $39.29, for a total value of $327,285.70.
  • On Wednesday, January 26th, Norman Payson sold 8,330 shares of Progyny stock. The shares were sold at an average price of $38.46, for a total value of $320,371.80.

Shares of PGNY opened at $40.47 on Friday. The business’s 50-day moving average is $44.30 and its two-hundred day moving average is $48.70. The company has a market capitalization of $3.71 billion, a P/E ratio of 61.32, a P/E/G ratio of 13.98 and a beta of 1.89. Progyny, Inc. has a fifty-two week low of $32.86 and a fifty-two week high of $68.32.

Progyny (NASDAQ:PGNYGet Rating) last announced its quarterly earnings results on Monday, February 28th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.11. The company had revenue of $127.55 million for the quarter, compared to the consensus estimate of $134.87 million. Progyny had a return on equity of 30.41% and a net margin of 13.14%. The firm’s revenue for the quarter was up 27.2% compared to the same quarter last year. During the same period last year, the firm earned $0.07 EPS. As a group, analysts predict that Progyny, Inc. will post 0.14 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of PGNY. BlackRock Inc. boosted its stake in shares of Progyny by 41.2% during the 3rd quarter. BlackRock Inc. now owns 7,787,503 shares of the company’s stock worth $436,101,000 after acquiring an additional 2,272,422 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Progyny by 407.4% during the 4th quarter. American Century Companies Inc. now owns 2,323,001 shares of the company’s stock worth $116,963,000 after acquiring an additional 1,865,151 shares in the last quarter. Macquarie Group Ltd. boosted its stake in shares of Progyny by 15.0% during the 3rd quarter. Macquarie Group Ltd. now owns 6,920,250 shares of the company’s stock worth $387,534,000 after acquiring an additional 900,432 shares in the last quarter. Riverbridge Partners LLC purchased a new stake in shares of Progyny during the 4th quarter worth about $40,901,000. Finally, Jennison Associates LLC boosted its stake in shares of Progyny by 53.7% during the 3rd quarter. Jennison Associates LLC now owns 1,630,742 shares of the company’s stock worth $91,322,000 after acquiring an additional 569,765 shares in the last quarter. 92.93% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently issued reports on PGNY. Zacks Investment Research raised Progyny from a “sell” rating to a “hold” rating in a research report on Wednesday, March 2nd. TheStreet downgraded Progyny from a “c-” rating to a “d+” rating in a research report on Friday, January 28th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $70.43.

Progyny Company Profile (Get Rating)

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

See Also

Insider Buying and Selling by Quarter for Progyny (NASDAQ:PGNY)

Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.